Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03409211 · ClinicalTrials.gov registry record · NA
Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT03409211: Completed NA study, sponsored by NYU Langone Health.
NCT03409211 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03409211, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a proof-of-principle, placebo-controlled, open label study to assess the improvement in the Treg counts and PASI Scores with PEVCO given at 1000 mg four times daily in patients with PsO (subjects may or may not have PsA) , who have active disease and are not currently receiving other therapy (as defined by the inclusion/exclusion criteria) compared to healthy subjects. The patients and healthy controls will receive placebo or PEVCO for a total of 9 weeks (3 weeks for placebo, followed by 6 weeks for PEVCO). No topical or systemic medications will be used during this period.
Primary Outcome
% change in the expansion of regulatory T cells; demonstrate an increase in %Treg at 6 weeks.
Interventions
- DIETARY_SUPPLEMENT PEVCO
- DIETARY_SUPPLEMENT Dietary Supplement Capsules without Coconut Oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-12-12 |
| Est. Completion | 2019-09-30 |
| Phase | NA |
What the finished NCT03409211 record still lists
NCT03409211 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which PEVCO is the first listed.
NCT03409211 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03409211 about?
NCT03409211 is a clinical study titled "Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis". This is a proof-of-principle, placebo-controlled, open label study to assess the improvement in the Treg counts and PASI Scores with PEVCO given at 1000 mg four times daily in patients with PsO (subjects may or may not have PsA) , who have active disease and are not currently receiving other therapy...
What is the current status of trial NCT03409211?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2017-12-12. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03409211?
The interventions under investigation include: PEVCO (DIETARY_SUPPLEMENT), Dietary Supplement Capsules without Coconut Oil (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03409211?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03409211's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI